BAFF-R CAR-T治疗B细胞肿瘤的研究进展

doi:10.11904/j.issn.1002-3070.2026.01.009

Abstract

Abstract: B cell-activating factor receptor(BAFF-R)is relatively stably expressed in various mature B-cell-derived tumors and is involved in maintaining the survival of tumor clones.Compared to traditional targets(such as CD19,etc.),BAFF-R is less likely to lead to immune escape due to antigen downregulation or loss,making it a promising immunotherapy target.In recent years,cellular immunotherapy targeting BAFF-R has gradually moved from experimental research to clinical applications,with chimeric antigen receptor T-cell(CAR-T)therapy emerging as a promising component of immunotherapy for B-cell tumors.This review will systematically elaborate on the biological basis of BAFF-R,the construction strategies of CAR-T,and the early clinical research progress of BAFF-R in various B-cell tumors.

Key words: B cell-activating factor receptor, chimeric antigen receptor T cell, immunotherapy, B cell malignancies

CLC Number:

R733

SU Shuai, XIAO Yi. Research progress on BAFF-R CAR-T therapy for B cell malignancies[J]. Journal of Practical Oncology, 2026, 40(1): 64-68.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2026.01.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2026/V40/I1/64

References

1 Lin H,Yang X,Ye S,et al.Antigen escape in CAR-T cell therapy:mechanisms and overcoming strategies[J].Biomed Pharmacother,2024,178:117252.
2 Rodig S J,Shahsafaei A,Li B,et al.BAFF-R,the major B cell-activating factor receptor,is expressed on most mature B cells and B-cell lymphoproliferative disorders[J].Hum Pathol,2005,36(10):1113-1119.
3 Smulski C R,Eibel H.BAFF and BAFF-receptor in B cell selection and survival[J].Front Immunol,2018,9:2285.
4 Almaden JV,Liu YC,Yang E,et al.B-cell survival and development controlled by the coordination of NF-κB family members RelB and cRel[J].Blood,2016,127(10):1276-1286.
5 Qin H,Dong Z,Wang X,et al.CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies[J].Sci Transl Med,2019,11(511):eaaw9414.
6 Luo Y,Qie Y,Gadd ME,et al.Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies[J].Cancer Immunol Immunother,2023,72(12):4031-4047.
7 Wang X,Dong Z,Awuah D,et al.CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia[J].Leukemia,2022,36(4):1015-1024.
8 Wong DP,Roy NK,Zhang K,et al.A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers[J].Nat Commun,2022,13(1):217.
9 Dong Z,Budde LE,Oh E,et al.Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies[J].Blood Adv,2024,8(15):4066-4076.
10 Del Real MM,Baird JH,Chen L,et al.Favorable safety profile and durable responses to PMB-CT01(BAFFR-CAR T cell)therapy in patients with B-cell lymphomas ineligible for or who failed CD19-targeted therapy,including CD19-negative disease[J].Blood,2024,144:3127.
11 Budde LE,Del Real M,Baird JH,et al.PMB-CT01(BAFFR-CAR T cell)therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy,including CD19-negative disease[J].J Clin Oncol,2024,42(16_suppl):6534-6534.
12 Caimi P,Spear MA,Liter J,et al.244A phase 1 study of novel transposon-based BAFF CAR-T cells(LMY-920)for treatment of relapsed or refractory non-hodgkin lymphoma(NHL)[J].Regular and Young Investigator Award Abstracts,2024:A282-A282.
13 Takahata H,Ohara N,Ichimura K,et al.BAFF-R is expressed on B-cell lymphomas depending on their origin,and is related to proliferation index of nodal diffuse large B-cell lymphomas[J].J Clin Exp Hematop,2010,50(2):121-127.
14 Zhang K,Roy NK,Vicioso Y,et al.BAFF receptor antibody for mantle cell lymphoma therapy[J].Oncoimmunology,2021,10(1):1893501.
15 Li YJ,Jiang WQ,Rao HL,et al.Expression of BAFF and BAFF-R in follicular lymphoma:correlation with clinicopathologic characteristics and survival outcomes[J].PLoS One,2012,7(12):e50936.
16 Xu X,Sun Q,Liang X,et al.Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies[J].Front Immunol,2019,10:2664.
17 Todorovic Z,Todorovic D,Markovic V,et al.CAR T cell therapy for chronic lymphocytic leukemia:successes and shortcomings[J].Curr Oncol,2022,29(5):3647-3657.
18 Haiat S,Billard C,Quiney C,et al.Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia[J].Immunology,2006,118(3):281-292.
19 Hengeveld PJ,Kersten MJ.B-cell activating factor in the pathophysiology of multiple myeloma:a target for therapy?[J].Blood Cancer J,2015,5(2):e282.
20 Wat J,Barmettler S.Hypogammaglobulinemia after chimeric antigen receptor(CAR)T-cell therapy:characteristics,management,and future directions[J].J Allergy Clin Immunol Pract,2022,10(2):460-466.

[1]	ZHAO Fengjuan, NONG Xiaolian, HUANG Shihuan, LI Fanrong, LU Feichen, YOU Xuemei. The effect of problem-solving therapy on depression,quality of life and immunotherapy outcomes in patients with advanced hepatocellular carcinoma:a randomized controlled trial [J]. Journal of Practical Oncology, 2026, 40(1): 30-40.
[2]	ZHANG Jianing, ZHANG Yi, ZHANG Xiaolian, LI Haiying, WANG Daqing. Research progress in immunotherapy for malignant tumors [J]. Journal of Practical Oncology, 2026, 40(1): 75-82.
[3]	ZHANG Xuan, LI Juan, FANG Chuanfeng, TIAN Hong, LIU Jiaren. Research progress of phytochemicals in tumor immunotherapy [J]. Journal of Practical Oncology, 2025, 39(5): 428-432.
[4]	MA Ming, WANG Wanying, RUAN Yuli, LIU Chao, ZHANG Yanqiao, MA Zhigang. The values of systemic inflammatory immune nutritional score in predicting the prognosis of immunotherapy for advanced gastric cancer [J]. Journal of Practical Oncology, 2025, 39(1): 39-48.
[5]	LI Caizheng, ZHENG Jing, SU Qiaoli. Advance progress in immunotherapy for unresectable locally advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2025, 39(1): 67-72.
[6]	XU Yaojie, CHANG Yihang, MO Piman, BAO Junjie. Research progress on disease characteristics and immune-related treatment of well-differentiated/dedifferentiated liposarcoma [J]. Journal of Practical Oncology, 2024, 38(4): 278-282.
[7]	ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors [J]. Journal of Practical Oncology, 2024, 38(1): 55-61.
[8]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[9]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[10]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[11]	LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(4): 372-376.
[12]	LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma [J]. Journal of Practical Oncology, 2023, 37(2): 144-148.
[13]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[14]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[15]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.

Research progress on BAFF-R CAR-T therapy for B cell malignancies

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments